Palbociclib Tablet

Form: Oral Tablets

Strength: 75 mg, 100mg, 125 mg

Reference Brands: Ibrance® (US & EU)

Category: Oncology Cancer Care

Palbociclib Tablets are a CDK 4/6 inhibitor used for the treatment of hormone receptor-positive (HR+), HER2-negative breast cancer. It works by blocking the proteins responsible for cancer cell division, halting cell cycle progression. Marketed under the brand name Ibrance®, Palbociclib is typically used in combination with letrozole or fulvestrant for the treatment of advanced or metastatic breast cancer. Available in 125 mg, 100 mg, and 75 mg tablet strengths, Palbociclib is manufactured in GMP-compliant facilities, making it a reliable and effective solution for oncology treatment in both US and EU markets.